ClonaCell™-HY Medium E

Hybridoma growth medium with hypoxanthine and thymidine (serum-containing)

Catalog # 03805 500 mL

STEMCELL™ TECHNOLOGIES
Scientists Helping Scientists™ | WWW.STEMCELL.COM
TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713
INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM
FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

ClonaCell™-HY Medium E is a serum-containing, nutritionally rich liquid medium optimized for hybridoma expansion after hypoxanthine, aminopterin, thymidine (HAT) selection. The medium contains hypoxanthine and thymidine (HT) and is used to wean hybridomas off aminopterin used during the selection process. This medium has been verified for use in mouse and rat hybridoma development and monoclonal antibody production and reportedly is compatible for production, cloning, and expansion of hybridomas using lymphocytes from a variety of host animals including human, mouse, rat, and hamster. ClonaCell™-HY Medium E has proven effective for subcloning and stabilization of unstable hybridoma cell lines.

Properties

Storage: Store at -20°C.

Shelf Life: Stable until expiry date (EXP) on label.

Contains:
- DMEM
- Pre-selected serum
- Hypoxanthine and thymidine (HT)
- Gentamicin
- 2-Mercaptoethanol
- Phenol red
- L-Glutamine and other supplements
- Other ingredients

Handling / Directions For Use

1. Thaw ClonaCell™-HY Medium E at room temperature (15 - 25°C) or overnight at 2 - 8°C. Mix well.
   NOTE: Do not thaw ClonaCell™-HY Medium E in a 37°C water bath.
2. If ClonaCell™-HY Medium E is not used immediately, store at 2 - 8°C for up to 2 weeks. Alternatively, aliquot and store at -20°C until expiry date as indicated on the label.

For further information, refer to the Technical Manual: ClonaCell™-HY Hybridoma Cloning Kit (Document #28411), available at www.stemcell.com or contact us to request a copy.

References

Chen ZC et al. (2000) Genes coding evolutionary novel anti-carbohydrate antibodies: Studies on anti-Gal production in alpha 1,3galactosyltransferase knock out mice. Mol Immunol 37(8): 455–66.
Flyak AI et al. (2015) Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160(5): 893–903.
García-Barreno B et al. (2014) Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. J Gen Virol 95(5): 1033–42.
Kaabinejadian S et al. (2016) Immunodominant West Nile virus T cell epitopes are fewer in number and fashionably late. J Immunol 196(10): 4263–73.
Loveless BC et al. (2011) Structural characterization and epitope mapping of the glutamic acid/alanine-rich protein from Trypanosoma congolense: Defining assembly on the parasite cell surface. J Biol Chem 286(23): 20658–65.
Okai S et al. (2016) High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice. Nat Microbiol 1(9): 16103.
Sapparapu G et al. (2016) Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540(7633): 443–7.

Smith SA et al. (2012) Persistence of circulating memory B cell clones with potential for Dengue virus disease enhancement for decades following infection. J Virol 86(5): 2665–75.
Spanier JA et al. (2016) Efficient generation of monoclonal antibodies against peptide in the context of MHCII using magnetic enrichment. Nat Commun 7: 11804.
Tan GS et al. (2014) Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of Group 2 influenza A virus hemagglutinin. J Virol 88(23): 13580–92.
Wittman VP et al. (2006) Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol 177(6): 4187–95.
Yew CW & Tan YJ. (2016) Generation of mouse monoclonal antibodies specific to chikungunya virus using ClonaCell-HY Hybridoma Cloning Kit. Methods Mol Biol 1426: 225–33.